DE3686646D1 - Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering". - Google Patents

Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering".

Info

Publication number
DE3686646D1
DE3686646D1 DE8686850416T DE3686646T DE3686646D1 DE 3686646 D1 DE3686646 D1 DE 3686646D1 DE 8686850416 T DE8686850416 T DE 8686850416T DE 3686646 T DE3686646 T DE 3686646T DE 3686646 D1 DE3686646 D1 DE 3686646D1
Authority
DE
Germany
Prior art keywords
recombinant dna
protein
sequence
fragment
dna molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686850416T
Other languages
English (en)
Other versions
DE3686646T2 (de
Inventor
Lars Abrahamsen
Tomas Moks
Bjoern Nilsson
Mathias Uhlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabigen AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabigen AB filed Critical Kabigen AB
Application granted granted Critical
Publication of DE3686646D1 publication Critical patent/DE3686646D1/de
Publication of DE3686646T2 publication Critical patent/DE3686646T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE8686850416T 1985-12-13 1986-12-02 Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering". Expired - Fee Related DE3686646T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8505922A SE8505922D0 (sv) 1985-12-13 1985-12-13 Construction of an igg binding protein to facilitate downstream processing using protein engineering

Publications (2)

Publication Number Publication Date
DE3686646D1 true DE3686646D1 (de) 1992-10-08
DE3686646T2 DE3686646T2 (de) 1993-04-08

Family

ID=20362468

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686850416T Expired - Fee Related DE3686646T2 (de) 1985-12-13 1986-12-02 Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering".

Country Status (11)

Country Link
US (1) US5143844A (de)
EP (1) EP0230869B1 (de)
JP (1) JPH0811069B2 (de)
AT (1) ATE80180T1 (de)
AU (1) AU600244B2 (de)
CA (1) CA1311430C (de)
DE (1) DE3686646T2 (de)
DK (1) DK600486A (de)
ES (1) ES2046177T3 (de)
GR (1) GR3006178T3 (de)
SE (1) SE8505922D0 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK528285D0 (da) * 1985-11-15 1985-11-15 Novo Industri As Peptider samt praeparater indeholdende disse
SE8505921D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab A method to export gene products to the growth medium of gram negative bacteria
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
DE3856559T2 (de) * 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
ATE87007T1 (de) * 1987-05-29 1993-04-15 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
US5084398A (en) * 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
DE3887750T2 (de) * 1987-11-20 1994-09-15 Creative Biomolecules Inc Selektive entfernung von immunkomplexen.
SE8800981A (sv) * 1988-03-17 1988-10-14 Lars Abrahamsen A recombinant fusion protein, its use and a recombinant vector
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8927008D0 (en) * 1989-11-29 1990-01-17 Ciba Geigy Novel process for the production of unfused protein in e.coli
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5595887A (en) * 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US6077694A (en) * 1990-09-21 2000-06-20 The United States Of America As Represented By The Department Of Health And Human Services Method for over-expression and rapid purification of biosynthetic proteins
US5863783A (en) * 1991-03-27 1999-01-26 Gist-Brocades, N.V. Cloning and expression of DNA molecules encoding arabinan-degrading enzymes of fungal origin
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US5989887A (en) * 1992-11-25 1999-11-23 Dsm N.V. Cloning and expression of DNA molecules incoding arabinan-degrading enzymes of fungal origin
SE9504019D0 (sv) * 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
DE60005806T2 (de) 1999-04-08 2004-08-05 Genentech, Inc., South San Francisco Zusammensetzung auf basis gegensätzlich geladener polypeptide
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
SE0200943D0 (sv) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US20050003548A1 (en) * 2002-07-22 2005-01-06 Nikolay Korokhov Targeted adenoviral vector displaying immunoglobulin-binding domain and uses thereof
AU2004291833B2 (en) 2003-09-12 2010-08-26 Ipsen Biopharmaceuticals, Inc. Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
US7192738B2 (en) 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
DE05733048T1 (de) 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
KR101434682B1 (ko) 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
JP2008048607A (ja) 2006-08-22 2008-03-06 Chisso Corp Ｆｃ結合ドメインとカルシウム結合発光蛋白質との融合蛋白質、それをコードする遺伝子およびそれらの用途
GB2442118B (en) 2006-09-19 2011-08-17 Chisso Corp Process for production of recombinant proteins as a soluble form
CA2666053C (en) 2006-12-06 2011-03-29 Repligen Corporation Nucleic acids encoding recombinant protein a
US8198043B2 (en) 2006-12-08 2012-06-12 General Electric Company Two helix binders
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG162687A1 (en) * 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
CN102365361B (zh) 2009-03-24 2015-09-02 株式会社钟化 对免疫球蛋白具有亲和性的蛋白质和免疫球蛋白结合性亲和配体
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
US9175067B2 (en) 2010-03-08 2015-11-03 Ge Healthcare Bio-Sciences Ab Immunoglobulin G Fc region binding polypeptide
CN102844432A (zh) 2010-03-24 2012-12-26 株式会社钟化 特异性结合免疫球蛋白的蛋白质以及免疫球蛋白结合性亲和配体
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2654914B1 (de) 2010-12-20 2018-05-30 GE Healthcare BioProcess R&D AB Affinitätschromatographiematrix
CN103269761B (zh) 2010-12-20 2016-05-18 通用电气健康护理生物科学股份公司 亲和色谱基质
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US9284354B2 (en) 2011-03-25 2016-03-15 Kaneka Corporation Immunoglobulin-binding polypeptide
SG10201604559TA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
HRP20240230T1 (hr) 2011-10-11 2024-04-26 F. Hoffmann - La Roche Ag Poboljšani sklop bispecifičnih protutijela
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
WO2013147691A1 (en) 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
WO2015005859A1 (en) 2013-07-10 2015-01-15 Ge Healthcare Bio-Sciences Ab Mutated immunoglobulin-binding polypeptides
JP6491600B2 (ja) 2013-09-27 2019-03-27 株式会社カネカ アルカリ水溶液を用いた多孔質セルロースビーズの製造方法
MX2016014409A (es) 2014-05-06 2017-01-20 Genentech Inc Produccion de proteinas heteromultimericas usando celulas de mamifero.
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3252158A4 (de) 2015-01-26 2018-07-18 Kaneka Corporation Mutantes immunglobulin-kappa-ketten-bindendes protein mit variabler region
WO2016121701A1 (ja) 2015-01-26 2016-08-04 株式会社カネカ 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス
JP6424101B2 (ja) * 2015-01-30 2018-11-14 Jnc株式会社 Ｆｃ結合ドメインとカルシウム結合発光蛋白質との融合蛋白質、それをコードする遺伝子およびそれらの用途
CN107428807A (zh) 2015-02-05 2017-12-01 三菱化学株式会社 对免疫球蛋白具有亲和性的蛋白质和使用它的亲和分离剂、液相色谱柱
WO2017195638A1 (ja) 2016-05-09 2017-11-16 株式会社カネカ 抗体またはκ鎖可変領域含有抗体断片の精製方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3455243B1 (de) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Trennmatrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455240A1 (de) 2016-05-11 2019-03-20 GE Healthcare BioProcess R&D AB Verfahren zum speichern einer trennmatrix
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US11779860B2 (en) 2017-08-07 2023-10-10 Repligen Corporation Fc binding proteins with cysteine in the C-terminal helical region
GB202018588D0 (en) 2020-11-26 2021-01-13 Cytiva Bioprocess R & D Ab Separation matrix
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta

Also Published As

Publication number Publication date
EP0230869A3 (en) 1988-08-03
EP0230869B1 (de) 1992-09-02
AU600244B2 (en) 1990-08-09
ES2046177T3 (es) 1994-02-01
JPS62190087A (ja) 1987-08-20
JPH0811069B2 (ja) 1996-02-07
DE3686646T2 (de) 1993-04-08
GR3006178T3 (de) 1993-06-21
DK600486D0 (da) 1986-12-12
US5143844A (en) 1992-09-01
EP0230869A2 (de) 1987-08-05
AU6633186A (en) 1987-06-18
SE8505922D0 (sv) 1985-12-13
CA1311430C (en) 1992-12-15
ATE80180T1 (de) 1992-09-15
DK600486A (da) 1987-06-14

Similar Documents

Publication Publication Date Title
DE3686646D1 (de) Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels "protein-engineering".
Kodaira et al. The dnaX gene encodes the DNA polymerase III holoenzyme τ subunit, precursor of the γ subunit, the dnaZ gene product
Rüther et al. Easy identification of cDNA clones.
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
Ishii et al. The nucleotide sequence of the cloned nusA gene and its flanking region of Escherichia coli
IL57491A (en) Recombinant dna,methods for the production thereof and proteins or polypeptides produced thereby
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
HK1013847A1 (en) Gdf-1 and uog-1 proteins
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
ATE294871T1 (de) Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
NO885659L (no) Mycobakterielle rekombinanter og peptider.
Lodwick et al. DNA sequence analysis of the imp UV protection and mutation operon of the plasmid TP110: identification of a third gene
US4816565A (en) Interleukin 2 receptor and a method for production thereof
JPS6420095A (en) Polypeptide having anti-blood coagulating action
Miele et al. Gene organization and nucleotide sequence of the primase region of IncP plasmids RP4 and R751
HUT52551A (en) Process for production of neutrophil-activizating factor
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
ATE46188T1 (de) Positionsspezifische proteolyse mittels renin.
EP0159943A3 (en) Expression vectors, dna fragments, peptides, hosts, and process for production of proteins
Prieto et al. Characterization, overproduction and purification of the product of gene 1 of Bacillus subtilis phage φ29
DK551786A (da) Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
EP0213463B1 (de) Interleukin-2 Rezeptor und Verfahren zu dessen Herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN AB, STOCKHOLM, SE

8339 Ceased/non-payment of the annual fee